Vaccines and Immunotherapy — Current Affairs 2026

Current Affairs Connections

Recent developments and news linked to Vaccines and Immunotherapy.

India's First Indigenous mRNA Vaccine for COVID-19 Receives Emergency Use Authorization

January 2024 (Hypothetical for future relevance)

Gennova Biopharmaceuticals' GEMCOVAC-19, India's first indigenously developed mRNA vaccine, receiving EUA marks a significant leap in India's medical biotechnology capabilities. This development positions India not just as a global vaccine manufacturer but also as an innovator in advanced vaccine platforms. It reduces reliance on foreign technology and strengthens India's pandemic preparedness, aligning with the 'Atmanirbhar Bharat' vision. From a UPSC perspective, this highlights the strategic importance of indigenous R&D and manufacturing capacity, particularly in cutting-edge technologies like mRNA, and its implications for public health and vaccine diplomacy.

UPSC Angle: Impact on India's self-reliance in biotechnology, implications for future pandemic response, role of public-private partnerships in R&D, and potential for export to developing nations.

CDSCO Approves India's First CAR-T Cell Therapy for Lymphoma and Leukemia

October 2023

The approval of NexCAR19 (developed by ImmunoACT and IIT Bombay) as India's first CAR-T cell therapy is a monumental achievement in cancer immunotherapy. This breakthrough makes advanced, personalized cell therapy accessible within India, potentially at a lower cost than imported alternatives. It signifies India's growing prowess in complex biological therapies and offers new hope for patients with refractory blood cancers. For UPSC, this underscores the advancements in medical biotechnology, the challenges of affordability and access for high-cost therapies, and the regulatory pathways for novel treatments in India. It also connects to the broader theme of 'personalized medicine approaches' [VY:SCI-07-02-03].

UPSC Angle: Significance of indigenous innovation in advanced therapies, challenges of cost and access for cutting-edge treatments, regulatory framework for cell and gene therapies, and future potential for cancer treatment in India.